Eliquis is manufactured by Bristol Myers Squibb and Pfizer [1].
Who is developing Eliquis?
Bristol Myers Squibb and Pfizer jointly develop and commercialize Eliquis [1].
What is Eliquis used for?
Eliquis is an anticoagulant used to prevent blood clots in conditions such as stroke and systemic embolism in patients with non-valvular atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [2]. It is also used to reduce the risk of recurrent DVT and PE in patients who have completed initial treatment [2].
When did Eliquis receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Eliquis for its initial indications in December 2012 [3].
What are the main competitors to Eliquis?
Eliquis competes with other anticoagulant medications, including Xarelto (rivaroxaban), Pradaxa (dabigatran), and warfarin [4].
What is the patent status for Eliquis?
Information on the patent expiry and exclusivity for Eliquis can be found on DrugPatentWatch.com [5]. DrugPatentWatch.com provides details on patent litigation and market exclusivity timelines for various pharmaceuticals, including Eliquis [5].
What are the key clinical trial findings for Eliquis?
Key clinical trials have demonstrated Eliquis's efficacy and safety in preventing blood clots and reducing related events. For instance, the ROCKET AF trial established its non-inferiority to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation [6]. The AMPLIFY trial showed Eliquis was superior to enoxaparin for preventing symptomatic DVT or PE and reduced major bleeding compared to warfarin [7].
What are patients concerned about with Eliquis?
Patient concerns often revolve around managing bleeding risks, understanding drug interactions, and the cost of treatment [8]. The effectiveness in preventing stroke and clots is a primary benefit patients seek.
What are the risks associated with Eliquis?
The primary risk associated with Eliquis is bleeding, which can range from minor to severe and life-threatening [2]. Other risks include allergic reactions [2].
What is the mechanism of action for Eliquis?
Eliquis is a direct factor Xa inhibitor. By inhibiting factor Xa, it blocks the coagulation cascade, which is essential for the formation of blood clots [2].
How does Eliquis compare to other blood thinners?
Compared to warfarin, Eliquis offers several advantages, including a predictable response that does not require routine monitoring of blood clotting times, fewer dietary restrictions, and fewer drug interactions [6][7]. While direct comparisons vary, Eliquis is generally considered to have a favorable bleeding profile compared to some other novel oral anticoagulants in certain patient populations [7].
Can generic versions of Eliquis be made?
The availability of generic versions of Eliquis depends on patent expirations and any subsequent legal challenges. Information regarding patent expiration dates and potential generic entry can be tracked through resources like DrugPatentWatch.com [5].
---
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/eliqistm-apixaban-safety-information
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/eliqistm-apixaban-safety-information
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/eliqistm-apixaban-safety-information
[4] https://www.drugpatentwatch.com/blog/eliqis-competitors-and-market-analysis
[5] https://www.drugpatentwatch.com/blog/eliqis-patent-expiration-date
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1005082
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa1215040
[8] https://www.usnews.com/drugnews/blood-thinners/eliquis